English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study

Perna, L., Stocker, H., Burow, L., Beyer, L., Trares, K., Kurz, C., et al. (2023). Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study. ALZHEIMERS RESEARCH & THERAPY, 15(1): 198. doi:10.1186/s13195-023-01341-3.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Perna, Laura1, Author           
Stocker, Hannah, Author
Burow, Lena, Author
Beyer, Leon, Author
Trares, Kira, Author
Kurz, Carolin, Author
Guersel, Selim, Author
Holleczek, Bernd, Author
Tato, Maia, Author
Beyreuther, Konrad, Author
Mons, Ute, Author
Gerwert, Klaus, Author
Perneczky, Robert, Author
Schoettker, Ben, Author
Brenner, Hermann, Author
Affiliations:
1Dept. Genes and Environment, Max Planck Institute of Psychiatry, Max Planck Society, ou_2035295              

Content

show
hide
Free keywords: -
 Abstract: Background Subjective cognitive complaints (SCC) have been mostly studied in the context of Alzheimer's disease in memory clinic settings. The potential of combining SCC with genetic information and blood biomarkers of neurodegenerative diseases for risk assessment of dementia and depression in the absence of dementia among community-dwelling older adults has so far not been explored.Methods Data were based on a population-based cohort of 6357 participants with a 17-year follow-up (ESTHER study) and a clinic-based cohort of 422 patients. Participants of both cohorts were grouped according to the diagnosis of dementia (yes/no) and the diagnosis of depression in the absence of dementia (yes/no). Participants without dementia included both cognitively unimpaired participants and cognitively impaired participants. Genetic information (APOE epsilon 4 genotype) and blood-based biomarkers of neurodegenerative diseases (glial fibrillary acidic protein; GFAP, neurofilament light chain; NfL, phosphorylated tau181; p-tau181) were available in the ESTHER study and were determined with Simoa Technology in a nested case-control design. Logistic regression models adjusted for relevant confounders were run for the outcomes of all-cause dementia and depression in the absence of dementia.Results The results showed that persistent SCC were associated both with increased risk of all-cause dementia and of depression without dementia, independently of the diagnostic setting. However, the results for the ESTHER study also showed that the combination of subjective complaints with APOE epsilon 4 and with increased GFAP concentrations in the blood yielded a substantially increased risk of all-cause dementia (OR 5.35; 95%CI 3.25-8.81, p-value < 0.0001 and OR 7.52; 95%CI 2.79-20.29, p-value < 0.0001, respectively) but not of depression. Associations of NfL and p-tau181 with risk of all-cause dementia and depression were not statistically significant, either alone or in combination with SCC, but increased concentrations of p-tau181 seemed to be associated with an increased risk for depression.Conclusion In community and clinical settings, SCC predict both dementia and depression in the absence of dementia. The addition of GFAP could differentiate between the risk of all-cause dementia and the risk of depression among individuals without dementia.

Details

show
hide
Language(s):
 Dates: 2023
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: ALZHEIMERS RESEARCH & THERAPY
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 15 (1) Sequence Number: 198 Start / End Page: - Identifier: -